Loading
DAT-1604 is an experimental small molecule from Danatlas Pharmaceuticals, in phase 1 trials for advanced solid tumours.
DAT-1604 is a small molecule (oral tablet) from Danatlas Pharmaceuticals. A selective oral small-molecule inhibitor of DNA polymerase theta (Pol θ). Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06998173 not yet recruiting (registry, 3 Nov 2026). Whether it works in people has not been established unless a trial below reports it.
A selective oral small-molecule inhibitor of DNA polymerase theta (Pol θ). Connects to POLQ.
1.DAT-1604 slips into a pocket on POLQ.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"DAT-1604" OR ABSTRACT:"DAT-1604") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about DAT-1604, not a curated reading list.
Shares Danatlas Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Danatlas Pharmaceuticals and the tag pipeline.
Shares Danatlas Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares POLQ, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares POLQ and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/